{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:38:55Z","timestamp":1793389135016,"version":"4.5.0"},"reference-count":92,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>This review summarizes the complex relationship between medications used to treat type 2 diabetes and bone health. T2DM patients face an increased fracture risk despite higher bone mineral density; thus, we analyzed the impact of key drug classes, including Metformin, Sulphonylureas, SGLT-2 inhibitors, DPP-4 inhibitors, GLP-1 agonists, and Thiazolidinediones. Metformin, despite promising preclinical results, lacks a clear consensus on its role in reducing fracture risk. Sulphonylureas present conflicting data, with potential neutral effects on bone. SGLT-2 inhibitors seem to have a transient impact on serum calcium and phosphorus, but evidence on their fracture association is inconclusive. DPP-4 inhibitors emerge as promising contributors to bone health, and GLP-1 agonists exhibit positive effects on bone metabolism, reducing fracture risk. Thiazolidinediones, however, demonstrate adverse impacts on bone, inducing loss through mesenchymal stem cell effects. Insulin presents a complex relationship with bone health. While it has an anabolic effect on bone mineral density, its role in fracture risk remains inconsistent. In conclusion, a comprehensive understanding of diabetes medications\u2019 impact on bone health is crucial. Further research is needed to formulate clear guidelines for managing bone health in diabetic patients, considering individual profiles, glycemic control, and potential medication-related effects on bone.<\/jats:p>","DOI":"10.3390\/medicina60030393","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T07:51:39Z","timestamp":1708933899000},"page":"393","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Effect of Drugs Used in Pharmacotherapy of Type 2 Diabetes on Bone Density and Risk of Bone Fractures"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5167-3369","authenticated-orcid":false,"given":"Agnieszka","family":"Wikarek","sequence":"first","affiliation":[{"name":"Student Scientific Society at the Department of Internal Medicine, Autoimmune and Metabolic Diseases, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5287-2551","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Grabarczyk","sequence":"additional","affiliation":[{"name":"Student Scientific Society at the Department of Internal Medicine, Autoimmune and Metabolic Diseases, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5412-5632","authenticated-orcid":false,"given":"Katarzyna","family":"Klimek","sequence":"additional","affiliation":[{"name":"Student Scientific Society at the Department of Internal Medicine, Autoimmune and Metabolic Diseases, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6118-6422","authenticated-orcid":false,"given":"Agata","family":"Janoska-Gawro\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Autoimmune and Metabolic Diseases, School of Medicine, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Suchodolska","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Autoimmune and Metabolic Diseases, School of Medicine, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3289-1050","authenticated-orcid":false,"given":"Micha\u0142","family":"Holecki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Autoimmune and Metabolic Diseases, School of Medicine, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2016). Global Report on Diabetes, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.metabol.2014.09.002","article-title":"Type 2 diabetes mellitus and fracture risk","volume":"63","author":"Dede","year":"2014","journal-title":"Metabolism"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jocd.2017.06.011","article-title":"Fracture Risk Assessment in Patients with Diabetes Mellitus","volume":"20","author":"Poiana","year":"2017","journal-title":"J. Clin. Densitom."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nrendo.2016.153","article-title":"IOF Bone and Diabetes Working Group.Mechanisms of diabetes mellitus-induced bone fragility","volume":"13","author":"Napoli","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.tem.2022.02.006","article-title":"Assessment and treatment of osteoporosis and fractures in type 2 diabetes","volume":"33","author":"Sheu","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_6","first-page":"7608964","article-title":"Pathophysiology and Management of Type 2 Diabetes Mellitus Bone Fragility","volume":"2020","author":"Cairoli","year":"2020","journal-title":"J. Diabetes Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S2213-8587(21)00347-8","article-title":"Bone fragility in diabetes: Novel concepts and clinical implications","volume":"10","author":"Hofbauer","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"National Osteoporosis Foundatio. Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos. Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1002\/jbmr.3214","article-title":"The Effect of Intentional Weight Loss on Fracture Risk in Persons with Diabetes: Results from the Look AHEAD Randomized Clinical Trial","volume":"32","author":"Johnson","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.phrs.2017.11.020","article-title":"Metformin promotes the proliferation and differentiation of murine preosteoblast by regulating the expression of sirt6 and oct4","volume":"129","author":"Mu","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1620\/tjem.241.13","article-title":"Metformin Enhances Osteogenesis and Suppresses Adipogenesis of Human Chorionic Villous Mesenchymal Stem Cells","volume":"241","author":"Gu","year":"2017","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1210\/er.2012-1042","article-title":"The impact of diabetes and diabetes medications on bone health","volume":"36","author":"Gilbert","year":"2015","journal-title":"Endocr. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.bbrc.2008.08.034","article-title":"Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression","volume":"375","author":"Kanazawa","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2006.02.030","article-title":"Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture","volume":"536","author":"Cortizo","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-2007-992786","article-title":"Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells","volume":"116","author":"Schurman","year":"2008","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1359\/jbmr.090732","article-title":"Effect of metformin on bone marrow progenitor cell differentiation: In vivo and in vitro studies","volume":"25","author":"Molinuevo","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"115325","DOI":"10.1016\/j.bone.2020.115325","article-title":"Metformin therapy and hip fracture risk among patients with type II diabetes mellitus: A population-based cohort study","volume":"135","author":"Oh","year":"2020","journal-title":"Bone"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s00125-005-1786-3","article-title":"Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk","volume":"48","author":"Vestergaard","year":"2005","journal-title":"Diabetologia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1038603","DOI":"10.3389\/fendo.2022.1038603","article-title":"Association of metformin use with fracture risk in type 2 diabetes: A systematic review and meta-analysis of observational studies","volume":"13","author":"Wang","year":"2023","journal-title":"Front. Endocrinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00198-015-3123-0","article-title":"Oral anti-diabetic drugs and fracture risk, cut to the bone: Safe or dangerous? A narrative review","volume":"26","author":"Palermo","year":"2015","journal-title":"Osteoporos. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1210\/jc.2009-0572","article-title":"Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes","volume":"95","author":"Zinman","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13098-017-0232-2","article-title":"Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: A randomized controlled trial","volume":"9","author":"Vianna","year":"2017","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/obr.12885","article-title":"The use of metformin, insulin, sulphonylureas, and thiazolidinediones and the risk of fracture: Systematic review and meta-analysis of observational studies","volume":"20","author":"Hidayat","year":"2019","journal-title":"Obes. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40266-013-0081-0","article-title":"Sulfonylureas and risk of falls and fractures: A systematic review","volume":"30","author":"Lapane","year":"2013","journal-title":"Drugs Aging"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00125-017-4269-4","article-title":"Diabetes, bone and glucose-lowering agents: Basic biology","volume":"60","year":"2017","journal-title":"Diabetologia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"735824","DOI":"10.3389\/fendo.2021.735824","article-title":"Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF02561404","article-title":"Suggestion of a deficient osteoblastic function in diabetes mellitus: The possible cause of osteopenia in diabetics","volume":"45","author":"Hernandez","year":"1989","journal-title":"Calcif. Tissue Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"107990","DOI":"10.1016\/j.diabres.2019.107990","article-title":"Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis","volume":"159","author":"Zhang","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s40520-020-01736-4","article-title":"Sulfonylureas use and fractures risk in elderly patients with type 2 diabetes mellitus: A meta-analysis study","volume":"33","author":"Tao","year":"2021","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"777861","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review","volume":"8","year":"2021","journal-title":"Front. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101175","DOI":"10.1016\/j.bonr.2022.101175","article-title":"Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes\u2014Data from a randomized, placebo-controlled study","volume":"16","author":"Rau","year":"2022","journal-title":"Bone Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2215\/CJN.04530418","article-title":"Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis","volume":"14","author":"Petrykiv","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12933-023-01743-5","article-title":"The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (\u226575 years): A retrospective, pharmacovigilance study","volume":"22","author":"Goldman","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/IJNRD.S234282","article-title":"Clinical Evaluation of Dapagliflozin in the Management of CKD: Focus on Patient Selection and Clinical Perspectives","volume":"15","author":"Nashar","year":"2022","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00198-023-06908-2","article-title":"Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"34","author":"Wang","year":"2023","journal-title":"Osteoporos. Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1463-1326.2012.01630.x","article-title":"Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin","volume":"14","author":"Ljunggren","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2040622320961599","DOI":"10.1177\/2040622320961599","article-title":"Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials","volume":"11","author":"Lou","year":"2020","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s00125-019-4955-5","article-title":"Canagliflozin and fracture risk in individuals with type 2 diabetes: Results from the CANVAS Program","volume":"62","author":"Zhou","year":"2019","journal-title":"Diabetologia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1007\/s00125-018-4663-6","article-title":"Use of SGLT2 inhibitors in type 2 diabetes: Weighing the risks and benefits","volume":"61","author":"Lupsa","year":"2018","journal-title":"Diabetologia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fphar.2017.00487","article-title":"Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms","volume":"8","author":"Yang","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kitaura, H., Ogawa, S., Ohori, F., Noguchi, T., Marahleh, A., Nara, Y., Pramusita, A., Kinjo, R., Ma, J., and Kanou, K. (2021). Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126578"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"101455","DOI":"10.1016\/j.jocd.2023.101455","article-title":"Meta-Analysis on the Association Between DPP-4 Inhibitors and Bone Mineral Density and Osteoporosis","volume":"27","author":"Huang","year":"2024","journal-title":"J. Clin. Densitom."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2337\/dc11-1099","article-title":"Dipeptidyl peptidase-4 inhibitors and bone fractures: A meta-analysis of randomized clinical trials","volume":"34","author":"Monami","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s00198-017-4051-y","article-title":"Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data","volume":"28","author":"Dombrowski","year":"2017","journal-title":"Osteoporos. Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1007\/s00198-016-3595-6","article-title":"Risk of fractures and diabetes medications: A nationwide cohort study","volume":"27","author":"Choi","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/dom.14261","article-title":"Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study","volume":"23","author":"Han","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Cai, T.T., Li, H.Q., Jiang, L.L., Wang, H.Y., Luo, M.H., Su, X.F., and Ma, J.H. (2021). Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study. BioMed Res. Int., 2021.","DOI":"10.1155\/2021\/3361309"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e3168","DOI":"10.1002\/dmrr.3168","article-title":"Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials","volume":"35","author":"Cheng","year":"2019","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"369","DOI":"10.21037\/atm.2019.06.74","article-title":"Effects of GLP-1 receptor analogue liraglutide and DPP-4 inhibitor vildagliptin on the bone metabolism in ApoE\u2212\/\u2212 mice","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/jcp.22243","article-title":"Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor","volume":"225","author":"Moreno","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fendo.2013.00073","article-title":"Beyond glycemic control in diabetes mellitus: Effects of incretin-based therapies on bone metabolism","volume":"4","author":"Ceccarelli","year":"2013","journal-title":"Front. Endocrinol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.stemcr.2016.02.002","article-title":"Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through \u03b2-catenin","volume":"6","author":"Meng","year":"2016","journal-title":"Stem Cell Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/bcp.12777","article-title":"Glucagon-like peptide-1(GLP-1) receptor agonists: Potential to reduce fracture risk in diabetic patients?","volume":"81","author":"Luo","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)","volume":"270","author":"Lehmann","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/CIRCULATIONAHA.104.475673","article-title":"Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets","volume":"115","author":"Brown","year":"2007","journal-title":"Circulation"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1359\/jbmr.1998.13.3.371","article-title":"Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: Implications for osteopenic disorders","volume":"13","author":"Nuttall","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1210\/en.2004-0735","article-title":"Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation","volume":"146","author":"Ali","year":"2005","journal-title":"Endocrinology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/nm1672","article-title":"PPAR-gamma regulates osteoclastogenesis in mice","volume":"13","author":"Wan","year":"2007","journal-title":"Nat. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/SHK.0b013e3181cc0738","article-title":"Thiazolidinediones inhibit TNF-alpha-mediated osteoclast differentiation of RAW264.7 macrophages and mouse bone marrow cells through downregulation of NFATc1","volume":"33","author":"Yang","year":"2010","journal-title":"Shock"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.08.010","article-title":"Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials","volume":"68","author":"Zhu","year":"2014","journal-title":"Bone"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2006-2646","article-title":"The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: A randomized, controlled trial","volume":"92","author":"Grey","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1210\/jc.2005-2226","article-title":"Thiazolidinedione use and bone loss in older diabetic adults","volume":"91","author":"Schwartz","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1007\/s00125-015-3660-2","article-title":"The effect of thiazolidinediones on bone mineral density and bone turnover: Systematic review and meta-analysis","volume":"58","author":"Billington","year":"2015","journal-title":"Diabetologia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/cbf.1668","article-title":"Insulin stimulates osteoblast proliferation and differentiation through ERK and PI3K in MG-63 cells","volume":"28","author":"Yang","year":"2010","journal-title":"Cell Biochem. Funct."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s002239900163","article-title":"Insulin increases histomorphometric indices of bone formation In vivo","volume":"59","author":"Cornish","year":"1996","journal-title":"Calcif. Tissue Int."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF03343726","article-title":"Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology","volume":"23","author":"Kemink","year":"2000","journal-title":"J. Endocrinol. Investig."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/jbmr.5650040610","article-title":"The characterization, regulation, and function of insulin receptors on osteoblast-like clonal osteosarcoma cell line","volume":"4","author":"Pun","year":"1989","journal-title":"J. Bone Miner. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.cell.2010.06.002","article-title":"Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition","volume":"142","author":"Fulzele","year":"2010","journal-title":"Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/jbmr.321","article-title":"The osteoblast: An insulin target cell controlling glucose homeostasis","volume":"26","author":"Clemens","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"E735","DOI":"10.1152\/ajpendo.00159.2005","article-title":"Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues","volume":"289","author":"Thrailkill","year":"2005","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e1552","DOI":"10.1210\/clinem\/dgaa963","article-title":"Insulin-like Growth Factor-1, Bone Mineral Density, and Fracture: A Mendelian Randomization Study","volume":"106","author":"Yuan","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1007\/s00125-004-1560-y","article-title":"Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire Cohort Study: Evidence for an indirect effect of insulin resistance?","volume":"47","author":"Dennison","year":"2004","journal-title":"Diabetologia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1210\/jc.2016-1726","article-title":"Association Between Insulin Resistance and Bone Structure in Nondiabetic Postmenopausal Women","volume":"101","author":"Shanbhogue","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"123","DOI":"10.11005\/jbm.2018.25.2.123","article-title":"Association of Insulin Resistance with Lower Bone Volume and Strength Index of the Proximal Femur in Nondiabetic Postmenopausal Women","volume":"25","author":"Yang","year":"2018","journal-title":"J. Bone Metab."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0377-1237(11)60120-2","article-title":"Evaluation of bone mineral density in type 2 diabetes mellitus patients before and after treatment","volume":"68","author":"Dutta","year":"2012","journal-title":"Med. J. Armed Forces India"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00198-017-4276-9","article-title":"The effect of insulin on bone mineral density among women with type 2 diabetes: A SWAN Pharmacoepidemiology study","volume":"29","author":"Ruppert","year":"2018","journal-title":"Osteoporos. Int."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1359\/jbmr.080323","article-title":"Fracture risk in type 2 diabetes: Update of a population-based study","volume":"23","author":"Melton","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/jbmr.3826","article-title":"Glycemic Control and Insulin Treatment Alter Fracture Risk in Older Men with Type 2 Diabetes Mellitus","volume":"34","author":"Lee","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00125-014-3289-6","article-title":"Fracture risk in diabetic elderly men: The MrOS study","volume":"57","author":"Napoli","year":"2014","journal-title":"Diabetologia"},{"key":"ref_84","first-page":"17","article-title":"Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: A retrospective database analysis in primary care","volume":"9","author":"Pscherer","year":"2016","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jdiacomp.2014.04.003","article-title":"Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial","volume":"28","author":"Rosenstock","year":"2014","journal-title":"J. Diabetes Complicat."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2337\/diacare.24.7.1198","article-title":"Diabetes and risk of fracture: The Blue Mountains Eye Study","volume":"24","author":"Ivers","year":"2001","journal-title":"Diabetes Care"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2337\/dc18-1965","article-title":"Frailty and Risk of Fractures in Patients with Type 2 Diabetes","volume":"42","author":"Li","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.amjms.2020.04.002","article-title":"Fracture Risk Assessment Tool May Not Indicate Bone Fragility in Women with Type 2 Diabetes","volume":"360","author":"Ohira","year":"2020","journal-title":"Am. J. Med. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00198-021-05934-2","article-title":"Influence of glycemic control and hypoglycemia on the risk of fracture in patients with diabetes mellitus: A systematic review and meta-analysis of observational studies","volume":"32","author":"Hidayat","year":"2021","journal-title":"Osteoporos. Int."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"101779","DOI":"10.1016\/j.berh.2022.101779","article-title":"Diabetes and osteoporosis\u2014Treating two entities: A challenge or cause for concern?","volume":"36","author":"Rasmussen","year":"2022","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ecl.2021.03.005","article-title":"Diabetes and Osteoporosis: Part I, Epidemiology and Pathophysiology","volume":"50","author":"Schacter","year":"2021","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ecl.2021.03.006","article-title":"Diabetes and Osteoporosis: Part II, Clinical Management","volume":"50","author":"Schacter","year":"2021","journal-title":"Endocrinol. Metab. Clin. N. Am."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/3\/393\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:04:49Z","timestamp":1760105089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/3\/393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":92,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["medicina60030393"],"URL":"https:\/\/doi.org\/10.3390\/medicina60030393","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]}}}